Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Molbio Diagnostics IPO
Price Band
₹768.0–807.0
Issue Size
₹939.7 Cr
Lot Size
18 shares
Min Investment
₹14,526
GMP
+₹120.0 (14.87%)
Issue Price
₹807.0
Subject to Sauda
₹1600
Paid only if allotted
Molbio Diagnostics IPO AI Summary
- Molbio Diagnostics IPO is listed on BSE, NSE in the Healthcare Research, Analytics & Technology sector.
- Price band: ₹768.0–₹807.0 per share, lot size 18 shares (min. investment ₹14,526).
- Subscription window: 10 Aug–12 Aug 2026, listing on 17 Aug 2026.
- Current GMP is +₹120.0 (14.87%), an estimated listing price of ₹927 — unofficial and can change daily.
Molbio Diagnostics Limited is set to offer its IPO with a strong subscription demand and a promising growth trajectory in the healthcare diagnostics sector. Investors should consider the company's fundamentals and market conditions when evaluating this investment opportunity.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Molbio Diagnostics IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 12 Aug 2026 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Overall Subscription
70.27x
| Category | Subscription | Status |
|---|---|---|
| QIB (Institutional) |
186.39x
|
186x 🔥 |
| NII (HNI) |
49.80x
|
50x ✓ |
| ↳ bNII (>₹10L) |
50.82x
|
51x ✓ |
| ↳ sNII (<₹10L) |
47.76x
|
48x ✓ |
| Retail (RII) |
12.97x
|
13x ✓ |
| Employee |
13.28x
|
13x ✓ |
| Total | 70.27x | 70.27x |
Auto-updated every 5 min · As of 12th Aug 2026 18:54
Molbio Diagnostics IPO Grey Market Premium (GMP) Today
GMP
+₹120.0
GMP %
+14.87%
Est. Listing
₹927.0
Updated: 17 Aug 2026 09:00
GMP Trend (Last 13 Days)
About the Company
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (“POC”) diagnostics company focused on delivering accurate, rapid, and cost-effective healthcare technologies for infectious and non-communicable diseases. The company has developed the ‘Truenat’ platform, a portable polymerase chain reaction (“PCR”) system that provides decentralized diagnosis within an hour, even in resource-limited settings. As of March 31, 2025, the platform is patented in over 100 countries and offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, HIV, and HPV through 42 assays. The ‘Truenat’ TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiary Prognosys, associate OptraScan, and collaboration partner UE Lifesciences. The company operates five manufacturing facilities in India – two in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Karnataka). These units manufacture diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems. The company has a global presence in over 80 countries with 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and through distributors to public health programs, diagnostic laboratories, and hospitals. The company generates revenues from device sales as well as recurring revenues from proprietary test kits. As of March 31, 2025, the company employed 1,000 permanent employees and 1,511 contract labourers.
Company Financials (₹ Cr)
As of 2026-03-31
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Key Ratios
EPS
₹14.56
NAV
₹84.51
ROE
16.20%
ROCE
20.98%
RoNW
15.23%
P/B Value
9.55
P/E Ratio
55.43
Market Cap
₹9299.87 Cr
PAT Margin
13.48%
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Vijaya Diagnostic Centre Ltd | 93.02 | 18.07% | 81.02 | 16.81 | 16.79 |
| Metropolis Healthcare Ltd | 72.98 | 12.56% | 63.72 | 9.19 | 9.19 |
| Dr. Lal Pathlabs Ltd | 145 | 20.78% | 62.2 | 30.24 | 30.2 |
| Poly Medicure Ltd | 306.45 | 10.37% | 52.61 | 31.79 | 31.75 |
| Molbio Diagnostics Ltd. This IPO | 101.51 | 14.55% | — | 14.77 | 14.77 |
Promoters
Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. 105.54 2 Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and 72.28 3 General Corporate Purposes 9.47 4 Issue Expenses 59.54 Total 246.83
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹840.66 Cr in the year ending 31 Mar 2024, rising to ₹1,027.94 Cr by 31 Mar 2025, and further increasing to ₹1,455.17 Cr by 31 Mar 2026. This demonstrates a consistent upward trend in revenue over the reported periods.
Profit Trend
Profit after tax was ₹83.54 Cr for the year ending 31 Mar 2024, increasing to ₹138.58 Cr by 31 Mar 2025, and further rising to ₹164.14 Cr by 31 Mar 2026. This indicates a positive trend in profitability across the periods.
Valuation
Priced at roughly 55.43 times trailing earnings, versus peers trading at a P/E range of 52.61 to 81.02.
Grey Market Premium, Explained
The grey market premium (GMP) indicates the expected listing price of an IPO compared to its issue price. A positive GMP suggests that the stock may list at a higher price, while a negative GMP indicates the opposite. GMP can be influenced by market sentiment and demand for the stock.
Subscription Demand
The IPO has seen strong demand, with a total subscription of 70.27 times as of 12th Aug 2026. The institutional category (QIB) was subscribed 186.39 times, while retail investors (RII) subscribed 12.97 times.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against the company's growth potential and market conditions. It is important to consider the company's fundamentals and future prospects.
Who May Want to Wait
Investors who are risk-averse or those who prefer stable, dividend-paying investments may want to avoid IPOs, as they can be more volatile and uncertain in the short term.
IPO Timeline, Explained
The IPO process includes several key dates: the opening date for subscription is 10th August 2026, closing on 12th August 2026. Allotment of shares will be on 13th August 2026, and the listing date is set for 17th August 2026.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when a stock lists at a higher price than its issue price. However, these gains are not guaranteed and can vary significantly based on market conditions and investor sentiment on the listing day.
This evaluation is generated from Molbio Diagnostics's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Molbio Diagnostics IPO GMP today?
Molbio Diagnostics IPO GMP today is +₹120.0 (14.87%), indicating an estimated listing price of ₹927. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Molbio Diagnostics IPO?
The price band of Molbio Diagnostics IPO is ₹768.0–₹807.0 per share.
When does Molbio Diagnostics IPO open and close?
Molbio Diagnostics IPO opens on 10 August 2026 and closes on 12 August 2026.
When does Molbio Diagnostics IPO list on the stock exchange?
Molbio Diagnostics IPO listed on 17 August 2026 at ₹927.0.
What is the lot size for Molbio Diagnostics IPO?
The lot size for Molbio Diagnostics IPO is 18 shares, requiring a minimum investment of ₹14,526.
What is the price band for the IPO?
The price band for the IPO is ₹768 to ₹807.
What is the minimum investment amount?
The minimum investment amount is ₹14,526.
What is the lot size for the IPO?
The lot size for the IPO is 18 shares.
When is the listing date?
The listing date is on 17th August 2026.
What does GMP mean?
GMP stands for Grey Market Premium, indicating the expected listing price of the IPO compared to its issue price.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
10 Aug 2026
Close
12 Aug 2026
Allotment
13 Aug 2026
Listing
17 Aug 2026
Similar IPOs in Healthcare Research, Analytics & Technology
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Molbio Diagnostics?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.